Ilumya (tildrakizumab-asmn)

Umxholo

• Yintoni ilumya?
• Ukuvunywa kwe-FDA
• Ilumya generic
• Iindleko ze-Ilumya
• Uncedo lwezezimali kunye neinshurensi
• I-Ilumya isebenzisa
• Ilumya kwi-plaque psoriasis
• Ukusetyenziswa okungavunyelwanga
• Ilumya idosi
• Iifom zamachiza kunye namandla
• Isisombululo se-plaque psoriasis
• Kuthekani ukuba ndiphose idosi?
• Ngaba kuya kufuneka ndisebenzise eli chiza ixesha elide?
• Iziphumo ebezingalindelekanga ze-Ilumya
• Iziphumo eziqhelekileyo ezichaphazelekayo
• Iziphumo ebezingalindelekanga ezimandundu
• Ukuphendula kwendawo yenaliti
• Urhudo
• Ukwanda komngcipheko wosulelo
• Ukuphendula komzimba ku-Ilumya
• Eminye indlela eya kwiIlumya
• Ilumya vs. iTremfya
• Malunga
• Sebenzisa
• Iifom zeziyobisi kunye nolawulo
• Iziphumo kunye neengozi
• Ukusebenza ngempumelelo
• Iindleko
• Ilumya vs ezinye iziyobisi
• Ilumya vs Cosentyx
• Ilumya vs Humira
• Ilumya vs. Enbrel
• Ilumya vs methotrexate
• Ukusetyenziswa kwe-Ilumya nezinye iziyobisi
• Ilumya kunye notywala
• Unxibelelwano lwe-Ilumya
• Ilumya kwaye ugonyo
• Ungamthatha njani u-Ilumya
• Ngaphambi kokuba uqale unyango lwe-Ilumya
• Ixesha
• Usebenza kanjani u-Ilumya
• Kuthatha ixesha elingakanani ukusebenza?
• Ilumya kunye nokukhulelwa
• Ilumya kunye nokuncancisa
• Imibuzo eqhelekileyo malunga ne-Ilumya
• Ngaba i-Ilumya iyayinyanga i-plaque psoriasis?
• Ndisoloko ndisebenzisa iikhrimu kwi-plaque psoriasis yam. Kutheni le nto kufuneka ndiqale ukufumana inaliti?
• Ndiza kuthatha ixesha elingakanani ukuthatha i-Ilumya?
• Yintoni iziyobisi zebhayoloji?
• Ngaba i-Ilumya isetyenziselwa ukunyanga i-psoriatic arthritis?
• Kutheni ndifuna uvavanyo lwe-TB phambi kokuba ndiqale unyango kunye no-Ilumya?
• Ndingenza ntoni ukuthintela usulelo ngelixa ndithatha i-Ilumya?
• Izilumkiso zika-Ilumya
• Ulwazi lobungcali ku-Ilumya
• Indlela yokusebenza
• I-Pharmacokinetics kunye ne-metabolism
• Ukungqinelana
• Isitofu
• Ukunyanga kwangaphambili
• Ukugcina

Yintoni ilumya?

I-Ilumya (tildrakizumab-asmn) ligama lonyango elinegama lebrendi elisetyenziselwa ukunyanga i-plaque psoriasis ephakathi. Imiselwe abantu abadala abakulungeleyo ukufumana unyango lwenkqubo (iziyobisi ezinikezwe ngenaliti okanye ethathwe ngomlomo) okanye i-phototherapy (unyango olulula).

Ilumya luhlobo lweziyobisi olubizwa ngokuba yi-monoclonal antibody. I-anti-monoclonal antibody yiprotein yenkqubo yomzimba yokuzikhusela eyilebhu. Ezi proteni zijolise kwiindawo ezithile zomzimba wakho. Luhlobo lonyango lwebhayoloji (iziyobisi ezivela kwizinto eziphilayo endaweni yeekhemikhali).

I-Ilumya iza ngethamo elinye lesirinji ekhethiweyo. Umboneleli wezempilo kwiofisi kagqirha wakho uyilawula ngokuyifaka ngaphakathi kwesikhumba sakho (inaliti engaphantsi).

Emva kweedosi ezimbini zokuqala, ezinikwa ukwahlukana iiveki ezine, u-Ilumya unikwa rhoqo kwiiveki ezili-12.

Kwizifundo zeklinikhi, phakathi kweepesenti ezingama-55 kunye neepesenti ezingama-58 zabantu abafumene i-Ilumya baneempawu ezincinci okanye ezisusiweyo ze-psoriasis emva kweeveki ezili-12. Ngaphezulu kwesibini kwisithathu sabantu abanezi ziphumo abagcine ngaphezulu kweeveki ezingama-64.

Ukuvunywa kwe-FDA

U-Ilumya wavunywa nguLawulo lokutya kunye noLawulo lweziyobisi (FDA) ngo-Matshi 2018.

Ilumya generic

I-Ilumya ifumaneka kuphela njengonyango lwegama lophawu. Okwangoku ayifumaneki ngendlela eqhelekileyo.

I-Ilumya iqulethe ichiza i-tildrakizumab, ekwabizwa ngokuba yi-tildrakizumab-asmn.

Iindleko ze-Ilumya

Njengawo onke amayeza, iindleko ze-Ilumya zingahluka.

Ixabiso lakho liya kuxhomekeka kwi-inshurensi yakho.

Uncedo lwezezimali kunye neinshurensi

Ukuba ufuna inkxaso yemali ukuhlawulela i-Ilumya, uncedo luyafumaneka.

I-Sun Pharma Global FZE, umvelisi we-Ilumya, uya kubonelela ngenkqubo ebizwa ngokuba yi-Ilumya Support Lighting the Way. Ngolwazi oluthe kratya, tsalela umnxeba ku-855-4ILUMYA (855-445-8692) okanye undwendwele I-Ilumya iwebhusayithi.

I-Ilumya isebenzisa

Ulawulo lokutya kunye neziyobisi (i-FDA) livuma amayeza amiselweyo anjengeIlumya ukunyanga iimeko ezithile. I-Ilumya inokusetyenziselwa ngaphandle kwelebheli kwezinye iimeko.

Ilumya kwi-plaque psoriasis

U-Ilumya uvunyiwe yi-FDA ukuba anyange i-plaque psoriasis ephakathi kubantu abadala abakulungeleyo ukufumana unyango lwenkqubo okanye i-phototherapy. Unyango lwenkqubo ngamayeza athathwe ngomlomo okanye ngenaliti kwaye asebenza kuwo wonke umzimba. I-Phototherapy (unyango olukhanyayo) lunyango olubandakanya ukuveza ulusu oluchaphazelekayo kukukhanya kwendalo okanye okwenziweyo kwe-ultraviolet.

Abantu abalulungeleyo unyango lwenkqubo okanye unyango lwefoto ngaba ngaba:

• ube ne-plaque psoriasis ephakathi, okanye
• Baye bazama unyango lwezihloko kodwa bafumanisa ukuba ezi zonyango azizilawulanga iimpawu zazo ze-psoriasis

NgokweSizwe sePsoriasis Foundation, i-plaque psoriasis ithathwa njengephakathi ukuba buhlungu kakhulu ukuba iiplathi zigubungela ngaphezulu kwepesenti ezintathu zomzimba wakho. Ukuthelekisa, isandla sakho sonke senza malunga neepesenti enye yomzimba wakho.

Ukuba unamacwecwe kwiindawo ezibuthathaka, ezinje ngezandla, iinyawo, ubuso, okanye amalungu esini, i-psoriasis yakho ikwajongwa njengephakathi.

Ukusetyenziswa okungavunyelwanga

I-Ilumya inokusetyenziselwa ngaphandle kwelebheli kwezinye iimeko. Ukusetyenziswa kwelebula engekho xa kusebenze iyeza elamkelweyo lokunyanga imeko enye emiselweyo ukunyanga imeko eyahlukileyo.

Isifo samathambo

I-Ilumya ayivunyelwanga ukunyanga i-psoriatic arthritis, kodwa inokumiselwa ngaphandle kwelebheli yale meko. I-Psoriatic arthritis ibandakanya iimpawu ze-psoriasis zolusu kunye neentlungu, ukudumba kwamalungu.

Kwisifundo esinye seklinikhi esincinci, u-Ilumya akazange aziphucule ngokubonakalayo iimpawu ze-psoriatic arthritis okanye iintlungu xa zisetyenziswa kwiiveki ze-16, xa kuthelekiswa ne-placebo (akukho nyango).

Nangona kunjalo, kwenziwa izifundo ezongezelelweyo ukuvavanya ukuba ingaba i-Ilumya iluncedo na kunyango lwe-psoriatic arthritis. Olunye uphononongo lweklinikhi lwexesha elide luyaqhubeka ngoku.

I-Ankylosing spondylitis

I-Ilumya ayivunyelwanga kunyango lwe-ankylosing spondylitis (isifo samathambo esichaphazela umqolo wakho). Nangona kunjalo, kukho isifundo sonyango esiqhubekayo sokuvavanya ukuba siyasebenza na kule meko.

Ilumya idosi

Olu lwazi lulandelayo luchaza idosi yesiqhelo ye-Ilumya. Nangona kunjalo, qiniseka ukuthatha idosi ekumisela ugqirha wakho. Ugqirha wakho uya kumisela eyona idosi ilungele iimfuno zakho.

Iifom zamachiza kunye namandla

I-Ilumya iza ngethamo elinye lesirinji ekhethiweyo. Isirinji nganye iqulethe i-100 mg ye-tildrakizumab kwi-1 ml yesisombululo.

I-Ilumya inikwa ngenaliti phantsi kolusu lwakho (subcutaneous).

Isisombululo se-plaque psoriasis

Ithamo elicetyiswayo le-Ilumya kwi-plaque psoriasis yenye yenaliti engaphantsi kwe-100-mg.

Uyakufumana inaliti yokuqala neyesibini ngaphandle kweeveki ezine. Emva kwedosi yesibini, uya kufumana onke amathamo ongezelelweyo rhoqo kwiiveki ezili-12. Umboneleli wezempilo kwiofisi kagqirha wakho uya kukunika inaliti nganye.

Kuthekani ukuba ndiphose idosi?

Ukuba ulibale ukuya kwi-ofisi kagqirha wakho ukufumana idosi, tsalela umnxeba ukucwangcisa kwakhona idinga lakho ngokukhawuleza nje ukuba ukhumbule. Emva koko, qhubeka kwakhona neshedyuli eqhelekileyo.

Umzekelo, ukuba sele ufumene idosi ezimbini zokuqala, uya kucwangcisa idosi elandelayo kwiiveki ezili-12 emva kwethamo lakho lokwenza.

Ngaba kuya kufuneka ndisebenzise eli chiza ixesha elide?

Oko kuyakuxhomekeka ekubeni wena kunye nogqirha wakho nigqibe ekubeni i-Ilumya ikhuselekile kwaye iyasebenza ekunyangeni i-psoriasis yakho. Ukuba uyakwenza oko, unokusebenzisa ichiza ixesha elide ukulawula iimpawu zakho ze-psoriasis.

Iziphumo ebezingalindelekanga ze-Ilumya

I-Ilumya inokubangela iziphumo ebezingalindelekanga ezinobulali okanye ezinobuzaza. Olu luhlu lulandelayo luqulathe ezinye zeziphumo ebezingalindelekanga ezinokubakho ngelixa uthatha u-Ilumya. Olu luhlu alubandakanyi zonke iziphumo ebezingalindelekanga ezinokubakho.

Ngolwazi oluthe kratya malunga neziphumo ebezingalindelekanga ze-Ilumya okanye iingcebiso ngendlela yokujongana nefuthe elibi, thetha nogqirha wakho okanye usokhemesti.

Iziphumo eziqhelekileyo ezichaphazelekayo

Iziphumo eziqhelekileyo ezichaphazelekayo ze-Ilumya zingabandakanya:

• izifo eziphezulu zokuphefumula
• iimpendulo zesiza senaliti
• urhudo

Uninzi lweziphumo ebezingalindelekanga zinokuhamba zingaphelanga iintsuku okanye iiveki ezimbalwa. Ukuba zinzima kakhulu okanye azihambi, thetha nogqirha wakho okanye usokhemesti.

Iziphumo ebezingalindelekanga ezimandundu

Iziphumo ezibi kakhulu ezivela kwi-Ilumya aziqhelekanga, kodwa zinokwenzeka. Shayela ugqirha wakho ngokukhawuleza ukuba unemiphumo emibi. Tsalela umnxeba ku-911 ukuba iimpawu zakho ziziva zisongela ubomi okanye ukuba ucinga ukuba unempilo kaxakeka.

Iziphumo ebezingalindelekanga ezimandundu zinokubandakanya ukusabela okungafunekiyo ku-Ilumya. Iimpawu zibandakanya:

• irhashalala
• ukucheba
• ukudumba komqala wakho, umlomo, okanye ulwimi, olunokubangela ingxaki ekuphefumleni
• i-angioedema (ukudumba phantsi kolusu lwakho, ubukhulu becala kwiinkophe zakho, imilebe, izandla, okanye iinyawo)

Ukuphendula kwendawo yenaliti

Kwizifundo zeklinikhi, ukusabela kwendawo yenaliti kwenzeka kwipesenti ezi-3 zabantu abafumene i-Ilumya. Iimpawu kwindawo yenaliti inokubandakanya:

• bomvu
• ukurhawuzelela ulusu
• iintlungu kwindawo yenaliti
• ukugruzuka
• ukudumba
• ukudumba
• ukopha

Ukuphendula kwesiza ngenaliti ngokubanzi akunzima kwaye kufuneka kuye kungaphelanga iintsuku ezimbalwa. Ukuba zinzima okanye azihambi, thetha nogqirha wakho.

Urhudo

Urhudo lwenzeka kwipesenti ezi-2 zabantu abafumene i-Ilumya kwizifundo zeklinikhi. Iziphumo ebezingalindelekanga zinokuhamba nokusetyenziswa gwenxa kweziyobisi. Ukuba isifo sohudo sinzima okanye sihlala ixesha elide kuneentsuku ezininzi, thetha nogqirha wakho.

Ukwanda komngcipheko wosulelo

Kwizifundo zeklinikhi, iipesenti ezingama-23 zabantu abafumene i-Ilumya bafumana usulelo. Kubalulekile ukuba uqaphele, nangona kunjalo, ukuba inani elifanayo losulelo lwenzeka kubantu abafumene i-placebo (akukho nyango).

Ezona zifo zixhaphakileyo kubantu abathatha i-Ilumya yayizizifo eziphezulu zokuphefumla, ezinje ngengqele eqhelekileyo. Ukuya kuthi ga kwiipesenti ze-14 zabantu kolu phando babenesifo sokuphefumla. Nangona kunjalo, phantse zonke izifo zazincinci okanye zingabi zibi. Ngaphantsi kweepesenti ze-0.3 zosulelo zithathwa njengezinzima.

I-Ilumya inyusa umngcipheko wosulelo kuba inciphisa ukusebenza kwamalungu athile omzimba wakho. Amajoni akho omzimba ayazikhusela kwizifo.

Phambi kokuba uqale unyango kunye no-Ilumya, ugqirha wakho uyakukukhangela usulelo, kubandakanya isifo sephepha (TB). Ukuba unembali ye-TB okanye une-TB esebenzayo, kuyakufuneka ufumane unyango lwaloo meko ngaphambi kokuba uqale ukuthatha i-Ilumya.

Ngalo lonke unyango lwakho lwe-Ilumya, kubalulekile ukuba unxibelelane nogqirha wakho ngoko nangoko ukuba uneempawu ze-TB. Oku kubandakanya umkhuhlane, iintlungu zemisipha, ukwehla kobunzima, ukukhwehlela, okanye igazi kwi-mucus yakho.

Ukuphendula komzimba ku-Ilumya

Kwizifundo zeklinikhi, ngaphantsi kwe-7 yepesenti yabantu abathatha i-Ilumya babenempendulo apho amajoni abo omzimba avelise izilwa-buhlungu ku-Ilumya.

Ii-antibodies ziiproteni ezilwa nezinto zangaphandle emzimbeni wakho njengabahlaseli. Umzimba unokwenza ii-antibodies kuyo nayiphi na into yangaphandle, kubandakanya ne-monoclonal antibodies ezinje nge-Ilumya.

Ukuba umzimba wakho uvelisa ii-antibodies ku-Ilumya, kunokwenzeka ukuba iyeza alinakuphinda lisebenze ekunyangeni i-psoriasis yakho. Kubalulekile ukuba uqaphele, nangona kunjalo, ukuba i-Ilumya yenziwe yasebenza kancinci kuphela malunga neepesenti ezi-3 zabantu abayifumeneyo.

Eminye indlela eya kwiIlumya

Amanye amayeza akhoyo anokunyanga i-plaque psoriasis ephakathi. Abanye banokukulungela ngcono kunabanye. Ukuba unomdla wokufumana enye indlela eya kwi-Ilumya, thetha nogqirha wakho ukuze ufunde ngakumbi ngamanye amayeza anokukusebenzela.

Imizekelo yezinye iziyobisi ezingasetyenziselwa ukunyanga i-plaque psoriasis ngokuqatha zibandakanya:

• imethotrexate (iOtrexup, iRasuvo, iTrexall)
• adalimumab (Humira)
• I-etanercept (i-Enbrel)
• secukinumab (iCosentyx)
• ustekinumab (uStelara)
• guselkumab (Tremfya)

Ilumya vs. iTremfya

Unokuzibuza ukuba i-Ilumya ithelekisa njani namanye amayeza amiselwe ukusetyenziswa okufanayo. Apha sijonga indlela i-Ilumya kunye neTremfya ezifanayo kunye ezahlukeneyo.

Malunga

I-Ilumya iqulethe i-tildrakizumab, eluhlobo lwesiyobisi ekuthiwa yi-monoclonal antibody. I-Tildrakizumab inqanda (iibhloko) umsebenzi weprotein ebizwa ngokuba yi-interleukin-23 (IL-23). Kwi-plaque psoriasis, le molekyuli iyabandakanyeka kulwakhiwo lweseli yesikhumba ekhokelela kumacwecwe.

I-Tremfya ikwalomzimba omzimba omnye othintela umsebenzi we-IL-23. Iqulethe ichiza guselkumab.

I-Ilumya kunye neTremfya zombini amachiza e-biologic anciphisa ukuvuvukala kwaye ancede ukuthintela ukwenziwa kwamacwecwe kubantu abane-psoriasis. I-Biologics ngamayeza enziwe ngezinto eziphilayo kuneekhemikhali.

Sebenzisa

I-Ilumya kunye neTremfya bobabini bavunyiwe yi-FDA ukunyanga i-plaque psoriasis kubantu abadala abafanelekileyo kunyango lwenkqubo okanye kwi-phototherapy.

Unyango lwenkqubo lubandakanya amayeza athathwe ngomlomo okanye ngenaliti esebenza kuwo wonke umzimba. I-Phototherapy ibandakanya ukuveza ulusu oluchaphazelekayo kukukhanya kwendalo okanye okwenziweyo kwe-ultraviolet.

Ezi ntlobo zonyango zihlala zisetyenziselwa ukumodareyitha i-plaque psoriasis okanye abantu abangaziphenduliyo iindlela zonyango (ezisetyenziswa kulusu).

Iifom zeziyobisi kunye nolawulo

I-Ilumya iza ngethamo elinye lesirinji ekhethiweyo equlathe i-100 mg ye-tildrakizumab. I-Ilumya inikezelwa ngenaliti phantsi kolusu (subcutaneous) kwiofisi kagqirha. Inaliti ezimbini zokuqala zinikwa ngokwahlukana iiveki ezine. Emva kweenaliti, idosi inikwa iiveki ezilishumi elinambini.

Njengo-Ilumya, i-Tremfya iza nesirinji ekhethiweyo yedosi enye, kodwa iqulethe i-100 mg ye-guselkumab. Kwakhona kunikwa njenge-injection subcutaneous. Kwaye ngo-Ilumya, iinaliti ezimbini zokuqala zinikwa iiveki ezine ngokwahlukana. Nangona kunjalo, onke amathamo emva koko anikwa rhoqo kwiiveki ezisibhozo.

I-Tremfya inokunikwa kwi-ofisi kagqirha wakho, okanye uzitofe ekhaya emva kokufumana uqeqesho olufanelekileyo kumboneleli wakho wezempilo.

Iziphumo kunye neengozi

Ilumya kunye neTremfya baneziphumo ebezingalindelekanga ezifanayo kwaye ezinye zahlukile. Imizekelo idweliswe apha ngezantsi.

Ukusebenza ngempumelelo

I-Ilumya kunye neTremfya khange zithelekiswe kwizifundo zeklinikhi, kodwa zombini ziyasebenza ekunyangeni i-plaque psoriasis ephakathi.

Ukuthelekisa ngokungathanga ngqo kweziyobisi ze-plaque psoriasis kufumanise ukuba iTremfya inokusebenza ngakumbi ekuphuculeni iimpawu kune-Ilumya. Kolu phando, abantu abathathe i-Tremfya babenamathuba angama-12.4 amathuba okuba baphuculwe ziipesenti ezingama-75, xa kuthelekiswa nabantu abathathe i-placebo (akukho nyango).

Kwisifundo esinye, abantu abathathe i-Ilumya babenamathuba ali-11 ngakumbi okuba neziphumo ezifanayo xa kuthelekiswa nendawo ye-placebo.

Iindleko

I-Ilumya kunye neTremfya zombini zinegama lophawu lweziyobisi. Okwangoku azikho iintlobo zohlobo oluthile lwamayeza. Amayeza egama leBrand ahlala exabisa ngaphezu kwegeneric.

I-Ilumya kunye neTremfya ngokubanzi zibiza malunga nokufanayo. Indleko ozihlawulela iziyobisi ziya kuxhomekeka kwisicwangciso sakho seinshurensi.

Ilumya vs ezinye iziyobisi

Ukongeza kwiTremfya, kukho ezinye iziyobisi ezininzi ezisetyenziselwa ukunyanga i-plaque psoriasis. Apha ngezantsi kukho uthelekiso phakathi kwe-Ilumya kunye namanye ala mayeza.

Ilumya vs Cosentyx

I-Ilumya iqulethe i-tildrakizumab, eluhlobo lweziyobisi ekuthiwa yi-monoclonal antibody. I-Tildrakizumab inqanda (iibhloko) umsebenzi weprotein ebizwa ngokuba yi-interleukin-23 (IL-23). Kwi-plaque psoriasis, le molekyuli iyabandakanyeka kulwakhiwo lweseli yesikhumba ekhokelela kumacwecwe.

ICosentyx ikwalomzimba omzimba omnye. Iqulethe ichiza secukinumab kunye neebhloko ze-interleukin-17A (IL-17A). Njenge-IL-23, i-IL-17A iyabandakanyeka kulwakhiwo lweeseli zolusu ezikhokelela kumacwecwe.

Nangona i-Ilumya kunye neCosentyx zombini ziziyobisi ze-biologic, zisebenza ngeendlela ezahlukeneyo.

I-Biologics ngamayeza enziwe kwizinto eziphilayo kuneekhemikhali.

Sebenzisa

I-Ilumya kunye neCosentyx bobabini bavunyiwe yi-FDA ukunyanga i-plaque psoriasis kubantu abadala abagqatswa kunyango lwenkqubo okanye kwi-phototherapy. Unyango lwenkqubo yonyango oluthathwa ngomlomo okanye ngenaliti kwaye lusebenza kuwo wonke umzimba. I-Phototherapy ibandakanya ukuveza ulusu oluchaphazelekayo kukukhanya kwe-ultraviolet.

ICosentyx ikwavunyiwe yi-FDA ukunyanga i-psoriatic arthritis (i-psoriasis ene-joint joint) kunye ne-ankylosing spondylitis (isifo samathambo emqolo).

Iifom zeziyobisi kunye nolawulo

I-Ilumya kunye neCosentyx zombini zinikwe njengeinaliti phantsi kolusu (subcutaneous).

U-Ilumya unikwa kwiofisi kagqirha ngumboneleli wezempilo. Inaliti ezimbini zokuqala zinikwa ngokwahlukana iiveki ezine. Emva kwezo ziphene zimbini, idosi inikwa iiveki ezilishumi elinambini. Idosi nganye yi-100 mg.

Idosi yokuqala yeCosentyx ihlala inikwa kwiofisi kagqirha. Emva koko, ichiza linokuthi litofelwe ekhaya emva koqeqesho olufanelekileyo nomboneleli wezempilo.

KwiCosentyx, inaliti ezimbini ze-150 mg (iyonke eyi-300 mg idosi nganye) inikwa iiveki ezintlanu. Emva koko, inaliti enye inikwa inyanga nenyanga. Elinye lala maxabiso li-300 mg, nangona abanye abantu benokufuna i-150 mg yedosi nganye.

Iziphumo kunye neengozi

I-Ilumya neCosentyx zineziphumo ebezingalindelekanga ezifanayo kwaye ezinye zahlukile. Imizekelo yeziphumo ebezingalindelekanga kuwo omabini la machiza zidweliswe apha ngezantsi.

Ukusebenza ngempumelelo

I-Ilumya kunye neCosentyx khange zithelekiswe kwizifundo zeklinikhi, kodwa zombini ziyasebenza ekunyangeni i-plaque psoriasis ephakathi.

Ukuthelekiswa okungangqalanga kwamayeza e-plaque psoriasis kufumanise ukuba iCosentyx inokusebenza ngakumbi kune-Ilumya ekuphuculeni iimpawu. Kolu phando, abantu abathathe i-300 mg yeCosentyx babengamaxesha ayi-17.5 amathuba okuba baphucule ipesenti ezingama-75 kwiimpawu xa kuthelekiswa nabantu abathathe i-placebo (akukho nyango).

Kwisifundo esinye, abantu abathathe i-Ilumya babenamathuba ali-11 okuba neziphumo ezifanayo, xa kuthelekiswa ne-placebo.

Iindleko

I-Ilumya kunye neCosentyx zombini zinegama lophawu lweziyobisi. Okwangoku azikho iifom zohlobo oluthile ezifumaneka nakweliphi na ichiza. Amayeza egama leBrand ahlala exabisa ngaphezu kwegeneric.

I-Ilumya kunye neCosentyx ngokubanzi zibiza malunga nokufanayo. Indleko ozihlawulela iziyobisi ziya kuxhomekeka kwisicwangciso sakho seinshurensi.

Ilumya vs Humira

I-Ilumya iqulethe i-tildrakizumab, eluhlobo lwesiyobisi ekuthiwa yi-monoclonal antibody. I-Tildrakizumab inqanda (iibhloko) umsebenzi weprotein ebizwa ngokuba yi-interleukin-23 (IL-23). Kwi-plaque psoriasis, le molekyuli iyabandakanyeka kulwakhiwo lweseli yesikhumba ekhokelela kumacwecwe.

I-Humira iqulethe ichiza i-adalimumab. Ikwayile antibody ye-monoclonal kwaye ibhloka umsebenzi weprotein ebizwa ngokuba yi-tumor necrosis factor-alpha (TNF-alpha). I-TNF-alpha ngumthunywa weekhemikhali obangela ukukhula okukhawulezayo kweeseli zolusu kwi-plaque psoriasis.

Nangona i-Ilumya neHumira zombini iziyobisi zebhayoloji ezithintela iinkqubo zomzimba, zisebenza ngeendlela ezahlukeneyo. I-Biologics ngamayeza enziwe kwizinto eziphilayo kuneekhemikhali.

Sebenzisa

U-Ilumya noHumira bobabini bavunyiwe yi-FDA ukuba banyange i-plaque psoriasis kubantu abadala abagqatswa kunyango lwenkqubo okanye kwi-phototherapy. Unyango lwenkqubo yonyango oluthathwa ngomlomo okanye ngenaliti kwaye lusebenza kuwo wonke umzimba. I-Phototherapy ibandakanya ukunyanga ulusu oluchaphazelekayo ngokukhanya kwe-ultraviolet.

I-Humira inezinye izinto ezisetyenzisiweyo ezamkelweyo ze-FDA, ezinye zazo zibandakanya:

• irheumatoid Arthritis
• isifo samathambo
• Isifo sikaCrohn
• i-ankylosing spondylitis
• ukudumba okwenziwa sisilonda sikabhobhosi

Iifom zeziyobisi kunye nolawulo

U-Ilumya noHumira bobabini banikwa njengezitofu phantsi kwesikhumba (sangaphantsi).

U-Ilumya unikwa kwiofisi kagqirha ngumboneleli wezempilo. Inaliti ezimbini zokuqala zinikwa ngokwahlukana iiveki ezine. Emva kwezo zitofu zimbini, iidosi zinikwa iiveki ezili-12 zonke. Idosi nganye yi-100 mg.

I-Humira ikwanikwe kwiofisi kagqirha, okanye njenge-self-injection ekhaya emva koqeqesho olufanelekileyo kumboneleli wezempilo. Idosi yokuqala yi-80 mg, ilandelwa yidosi ye-40-mg kwiveki enye kamva. Emva koko, idosi ye-40-mg inikwa iiveki ezimbini.

Iziphumo kunye neengozi

U-Ilumya noHumira basebenza ngeendlela ezahlukeneyo kodwa baneziphumo ebezingalindelekanga ezifanayo. Imizekelo yeziphumo ebezingalindelekanga eziqhelekileyo nezibi kwicala ngalinye leziyobisi zidweliswe apha ngezantsi.

UHumira uneebhokisi zezilumkiso ezivela kwi-FDA. Isilumkiso esinebhokisi lolona hlobo lomeleleyo lwesilumkiso esifunwa yi-FDA. Izilumkiso zithi u-Humira unyusa umngcipheko wosulelo olomeleleyo kunye nomhlaza othile.

Ukusebenza ngempumelelo

U-Ilumya noHumira abakhange bathelekiswe kwizifundo zeklinikhi, kodwa zombini ziyasebenza ekunyangeni i-plaque psoriasis ephakathi.

Olunye uthelekiso olungathanga ngqo lufumanise ukuba u-Ilumya usebenze malunga no-Humira njengonyango lwe-plaque psoriasis. Kolu phononongo, abantu abathathe naliphi na ichiza bebephantse babe li-15 amathuba okuba baphucule iimpawu kunabantu abathathe i-placebo (akukho nyango).

Nangona kunjalo, ngokusekwe kuhlalutyo lwamanye amachiza, uphononongo lucebise ukuba iziyobisi ezijolise kwi-IL-23, ezinje nge-Ilumya, zibonakala zisebenza ngakumbi ekunyangeni i-plaque psoriasis kune-TNF-blockers, ezinje ngeHumira. Izifundo ezingaphezulu ziyafuneka.

Iindleko

U-Ilumya noHumira bobabini banegama leziyobisi. Okwangoku azikho iintlobo zohlobo oluthile lwamayeza. Amayeza egama leBrand ahlala exabisa ngaphezu kwegeneric.

Nangona kunjalo, kukho iindlela ezininzi ze-biosimilar ze-adalimumab (iyeza laseHumira) ezivunyiweyo ukunyanga i-psoriasis. Oku kubandakanya iHyrimoz, iCyltezo, kunye neAmjevita. Amachiza e-Biosimilar ayafana nonyango lwebhayoloji asekwe kuyo, kodwa ayizizo iimpendulo ezichanekileyo. Amachiza e-biosimilar anokuxabisa malunga neepesenti ezingama-30 kunesiyobisi sokuqala.

I-Ilumya neHumira ngokubanzi zibiza malunga nokufanayo. Indleko ozihlawulela iziyobisi ziya kuxhomekeka kwisicwangciso sakho seinshurensi.

Ilumya vs. Enbrel

I-Ilumya iqulethe i-tildrakizumab, eluhlobo lwesiyobisi ekuthiwa yi-monoclonal antibody. I-Tildrakizumab inqanda (iibhloko) umsebenzi weprotein ebizwa ngokuba yi-interleukin-23 (IL-23). Kwi-plaque psoriasis, le molekyuli iyabandakanyeka kulwakhiwo lweseli yesikhumba ekhokelela kumacwecwe.

I-Enbrel ikwalomzimba omzimba omnye. Inayo ichiza etanercept, ethintela umsebenzi weprotein ebizwa ngokuba yi-tumor necrosis factor-alpha (TNF-alpha). I-TNF-alpha ngumthunywa weekhemikhali obangela ukukhula okukhawulezayo kweeseli zolusu kwi-plaque psoriasis.

Zombini i-Ilumya kunye ne-Enbrel ngamachiza e-biologic anciphisa ukwenziwa kwamacwecwe, kodwa enza ngeendlela ezahlukeneyo. I-Biologics ngamayeza enziwe kwizinto eziphilayo kuneekhemikhali.

Sebenzisa

I-Ilumya kunye ne-Enbrel bobabini bavunyiwe yi-FDA ukunyanga i-plaque psoriasis ngokulinganayo kubantu abadala abagqatswa kunyango lwenkqubo okanye kwi-phototherapy. Unyango lwenkqubo yonyango oluthathwa ngomlomo okanye ngenaliti kwaye lusebenza kuwo wonke umzimba. I-Phototherapy ibandakanya ukunyanga ulusu oluchaphazelekayo ngokukhanya kwe-ultraviolet.

I-Enbrel ikwavunyiwe ukuba inyange i-plaque psoriasis ngokulinganayo kubantwana abaneminyaka emi-4 nangaphezulu, kunye:

• irheumatoid Arthritis
• i-polyarticular juvenile idiopathic arthritis
• isifo samathambo
• i-ankylosing spondylitis

Iifom zeziyobisi kunye nolawulo

I-Ilumya kunye ne-Enbrel zombini zinikwe njengeinaliti phantsi kolusu (subcutaneous).

I-Ilumya iza ngethamo elinye lesirinji ekhethiweyo. Inikwa kwiofisi kagqirha ngumboneleli wakho wezempilo. Inaliti ezimbini zokuqala zinikwa ngokwahlukana iiveki ezine. Emva kwezo ziphene zimbini, idosi inikwa iiveki ezilishumi elinambini. Inaliti nganye yi-100 mg.

I-Enbrel inikwa kwiofisi kagqirha okanye njenge-self-injection ekhaya emva koqeqesho olufanelekileyo kumboneleli wezempilo. Kwiinyanga ezintathu zokuqala, u-Enbrel unikwa kabini ngeveki. Emva koko, idosi yesondlo inikwa kanye ngeveki. Idosi nganye yi-50 mg.

I-Enbrel ifumaneka ngeendlela ezininzi, kubandakanya idosi enye yesirinji ekhethiweyo kunye ne-autoinjector.

Iziphumo kunye neengozi

U-Ilumya no-Enbrel basebenza ngeendlela ezahlukeneyo kodwa baneziphumo ebezingalindelekanga ezifanayo. Imizekelo yeziphumo ebezingalindelekanga eziqhelekileyo nezibi kwicala ngalinye leziyobisi zidweliswe apha ngezantsi.

U-Enbrel uneebhokisi zezilumkiso ezivela kwi-FDA. Isilumkiso esinebhokisi lolona hlobo lomeleleyo lwesilumkiso esifunwa yi-FDA. Izilumkiso zichaza ukuba i-Enbrel inyusa umngcipheko wosulelo olomeleleyo kunye nomhlaza othile.

Ukusebenza ngempumelelo

I-Ilumya kunye ne-Enbrel zombini ziyasebenza ekunyangeni i-plaque psoriasis, kodwa i-Ilumya inokusebenza ngakumbi ekunciphiseni iimpawu zeplate.

Kwisifundo sonyango, iipesenti ezingama-61 zabantu abafumene i-Ilumya babenokuphuculwa kweempawu ubuncinci beepesenti ze-75. Kwelinye icala, iipesenti ezingama-48 zabantu abafumene i-Enbrel babenokuphucuka okufanayo.

Iindleko

I-Ilumya kunye ne-Enbrel zombini zineziyobisi ezinamagama. Okwangoku azikho iintlobo zohlobo oluthile lwamayeza. Amayeza egama leBrand ahlala exabisa ngaphezu kwegeneric.

I-Enbrel ibiza kancinci kune-Ilumya. Indleko ozihlawulela iziyobisi ziya kuxhomekeka kwisicwangciso sakho seinshurensi.

Ilumya vs methotrexate

I-Ilumya iqulethe i-tildrakizumab, eluhlobo lwesiyobisi ekuthiwa yi-monoclonal antibody. I-Tildrakizumab inqanda (iibhloko) umsebenzi weprotein ebizwa ngokuba yi-interleukin-23 (IL-23). Le molekyuli iyabandakanyeka kulwakhiwo lweseli yesikhumba ekhokelela kumacwecwe.

I-Methotrexate (i-Otrexup, i-Trexall, i-Rasuvo) luhlobo lweziyobisi ekuthiwa yi-antimetabolite, okanye i-folic acid antagonist (blocker). I-Methotrexate isebenza ngokuthintela umsebenzi we-enzyme ebandakanyeka ekukhuleni kweseli yolusu kunye nokwenziwa kwamatye.

I-Ilumya sisiyobisi se-biologic, ngelixa i-methotrexate lonyango oluqhelekileyo lwenkqubo.Unyango lwenkqubo lubhekisa kwiziyobisi ezithathwa ngomlomo okanye ngenaliti kwaye zisebenza kuwo wonke umzimba. I-Biologics ngamayeza enziwe kwizinto eziphilayo kuneekhemikhali.

Omabini la machiza anceda ukuphucula iimpawu ze-psoriasis ngokunciphisa ukwenziwa kwamatye.

Sebenzisa

I-Ilumya kunye ne-methotrexate zombini zivunyelwe yi-FDA ukunyanga i-plaque psoriasis ebukhali. I-Ilumya ikwavunyiwe ukuba inyange i-plaque psoriasis. I-Methotrexate yenzelwe ukuba isetyenziswe kuphela xa iimpawu zomntu ze-psoriasis zinzima okanye zikhubaza kwaye zingaphenduli kwamanye amayeza.

I-Methotrexate ikwavunyiwe ukuba inyange iintlobo ezithile zomhlaza kunye nesifo samathambo.

Iifom zeziyobisi kunye nolawulo

I-Ilumya inikezelwa ngenaliti phantsi kolusu (subcutaneous) kwiofisi kagqirha ngumboneleli wezempilo. Inaliti ezimbini zokuqala zinikwa ngokwahlukana iiveki ezine. Emva kweenaliti, idosi inikwa iiveki ezilishumi elinambini. Inaliti nganye yi-100 mg.

IMethotrexate iza njengecwecwe lomlomo, isisombululo solwelo, okanye inaliti. Ukunyanga i-plaque psoriasis, ihlala ithathwa ngomlomo. Ingathathwa njengethamo elinye kube kanye ngeveki, okanye njengeedosi ezintathu ezinikwe iiyure ezili-12 ngokwahlukeneyo kube kanye ngeveki.

Iziphumo kunye neengozi

I-Ilumya kunye ne-methotrexate zibangela iziphumo ebezingalindelekanga eziqhelekileyo nezibi. Iziphumo eziqhelekileyo nezibi kakhulu ezibonwayo kubantu abane-psoriasis zidweliswe apha ngezantsi. Olu luhlu alubandakanyi zonke iziphumo ebezingalindelekanga.

* IMethotrexate ineebhokisi zezilumkiso ezivela kwi-FDA echaza umngcipheko weziphumo ebezingalindelekanga ezichaziweyo ngasentla. Isilumkiso sebhokisi sisilumkiso esomeleleyo esifunwa yi-FDA. Yazisa oogqirha kunye nezigulana malunga neziphumo zeziyobisi ezinokuba yingozi.

Ukusebenza ngempumelelo

I-Ilumya kunye ne-methotrexate khange zithelekiswe ngokuthe ngqo kwizifundo zeklinikhi, kodwa zombini ziyasebenza ekunyangeni i-plaque psoriasis.

Olunye uthelekiso olungathanga ngqo lufumanise ukuba u-Ilumya wasebenza malunga ne-methotrexate ekuphuculeni iimpawu ze-plaque psoriasis. Nangona kunjalo, i-methotrexate yayinokubangela iziphumo ebezingalindelekanga ezibi xa kuthelekiswa ne-Ilumya.

Iindleko

I-Ilumya ifumaneka kuphela njengesiyobisi esinegama lophawu. Okwangoku azikho iifom zohlobo oluqhelekileyo ze-Ilumya. IMethotrexate iyafumaneka njengechiza elenza lafana nelo lenziwe nanjengegama leziyobisi elithi Trexall, Otrexup, neRasuvo. Amayeza egama leBrand ahlala exabisa ngaphezu kwegeneric.

I-Ilumya ibiza ngaphezulu kweefom zohlobo oluqhelekileyo kunye negama lophawu lweemethotrexate. Indleko ozihlawulayo ngazo naziphi na iintlobo zeli chiza ziya kuxhomekeka kwisicwangciso sakho seinshurensi.

Ukusetyenziswa kwe-Ilumya nezinye iziyobisi

I-Ilumya iyasebenza ekuphuculeni i-plaque psoriasis yodwa, kodwa inokusetyenziswa kunye namanye amayeza ngenzuzo eyongezelelweyo. Sebenzisa ngaphezulu kwendlela enye ukunyanga i-psoriasis kunokunceda ukucoca iiplagi ngokukhawuleza nokucoca ipesenti enkulu yamacwecwe.

Ukudityaniswa kwonyango kunokunciphisa idosi oyifunayo ngamanye amayeza e-psoriasis, anciphisa umngcipheko weziphumo ebezingalindelekanga. Ukongeza, unyango oluhlanganisiweyo lunokunciphisa umngcipheko wokuchasana ne-Ilumya (xa iyeza lingasasebenzi kuwe).

Imizekelo yezinye iindlela zonyango ezinokusetyenziswa ngokukhuselekileyo kunye ne-Ilumya zibandakanya:

• ii-corticosteroids, ezifana ne-betamethasone
• Iingqungquthela ze-vitamin D kunye namafutha (njengeDovonex kunye neVectical)
• methotrexate (Trexall, Otrexup, kunye neRasuvo)
• I-phototherapy (unyango olukhanyayo)

Ilumya kunye notywala

Akukho nxibelelwano lwaziwayo phakathi kotywala kunye no-Ilumya ngeli xesha. Nangona kunjalo, urhudo sisiphumo esisecaleni se-Ilumya kwabanye abantu. Ukusela utywala nako kunokubangela urhudo. Ke ngoko, ukusela utywala ngelixa ufumana unyango lwe-Ilumya kunokunyusa umngcipheko wakho.

Utywala bunokwenza ukuba unyango lwakho lwe-Ilumya lungasebenzi kakuhle. Oku kungenxa yeempembelelo zotywala kwi-psoriasis uqobo, kunye nefuthe elinokubakho kwindlela olandela ngayo isicwangciso sakho sonyango. Ukusetyenziswa kotywala kunoku:

• yonyusa ukudumba okunokukhokelela ekwakhiweni kweseli yolusu
• ukunciphisa amandla omzimba wakho wokulwa izifo kunye neengxaki zesikhumba
• kubangela ukuba ulibale ukuthatha amayeza akho okanye uyeke ukulandela isicwangciso sakho sonyango

Ukuba uthatha u-Ilumya kwaye unengxaki yokuphepha utywala, thetha nogqirha wakho malunga neendlela zokuthintela usulelo kunye nokuphucula amathuba akho onyango olunempumelelo kunye no-Ilumya.

Unxibelelwano lwe-Ilumya

U-Ilumya unonxibelelwano oluncinci lweziyobisi. Kungenxa yokuba i-Ilumya kunye nezinye ii-antibodies ze-monoclonal zenziwe umzimba, okanye zaphulwe, ngumzimba ngendlela eyahlukileyo kunaleyo ininzi yeziyobisi. (Iintsholongwane zeMonoclonal ngamachiza akhululwe elebhu evela kwiiseli zomzimba.)

Amachiza amaninzi, amayeza, kunye nezongezelelo zixutywe nee-enzymes kwisibindi sakho. I-Ilumya, kwelinye icala, i-metabolism ngendlela efanayo neeseli zomzimba ezenzeka ngokwasemzimbeni kunye neeproteni emzimbeni. Ngamafutshane, yaphukile ngaphakathi kwiiseli kuwo wonke umzimba wakho. Ngenxa yokuba i-Ilumya ayophuki esibindini sakho kunye nezinye iziyobisi, ngokubanzi ayisebenzisani nabo.

Ilumya kwaye ugonyo

Olunye unxibelelwano olubalulekileyo lwe-Ilumya zizitofu eziphilayo. Amayeza okugonya aphilayo kufuneka athintelwe ngexesha lonyango kunye no-Ilumya.

Amayeza okugonya aphilayo anexabiso elincinci leentsholongwane ezibuthathaka. Kuba u-Ilumya uvimba impendulo yesiqhelo yamajoni omzimba, umzimba wakho usenokungakwazi ukulwa intsholongwane kwisitofu sokugonya esiphilayo ngelixa uthatha ichiza.

Imizekelo yezitofu zokugonya eziphilayo ukuze ziphetshwe ngexesha lonyango lwe-Ilumya zibandakanya izitofu zokugonya:

• imasisi, uqwilikana, kunye nerubella (MMR)
• ingqakaqha
• umkhuhlane omthubi
• iqhwiqhwi
• ukujikeleza

Ngaphambi kokuba uqale unyango kunye no-Ilumya, thetha nogqirha wakho malunga nokuba unokufuna nasiphi na kwezi zitofu. Wena nogqirha wakho ninokuthatha isigqibo sokulibazisa unyango kunye no-Ilumya de kube emva kokuba nigonyiwe ngazo naziphi na izitofu eziphilayo eninokuzifuna.

Ungamthatha njani u-Ilumya

I-Ilumya inikezelwa ngenaliti phantsi kolusu (subcutaneous) ngumboneleli wezempilo kwiofisi kagqirha. Ingene esiswini sakho, emathangeni, okanye kwiingalo ezingaphezulu. Inaliti kwisisu sakho kufuneka ubuncinci zibe zii-intshi ezimbini kude nesisu sakho.

I-Ilumya akufuneki ukuba itofwe kwiindawo ezinamanxeba, amanqaku olulekileyo, okanye imithambo yegazi. Akufanelekanga ukuba ilawulwe kwiiplati, imivimbo, okanye kwiindawo ezibomvu okanye zethenda.

Ngaphambi kokuba uqale unyango lwe-Ilumya

Ngenxa yokuba u-Ilumya ewenza buthathaka amajoni akho omzimba, ugqirha wakho uyakukujonga isifo sephepha (TB) phambi kokuba uqale unyango. Ukuba une-TB esebenzayo, uyakufumana unyango lwe-TB ngaphambi kokuqala i-Ilumya. Kwaye ukuba wawukhe une-TB ngaphambili, kungafuneka unyangwe ngaphambi kokuba uqale i-Ilumya.

Kodwa nokuba awunazo iimpawu ze-TB, unokuba nefomu engasebenziyo ye-TB, ebizwa ngokuba yi-TB efihlakeleyo. Ukuba unayo i-TB efihlakeleyo kwaye uthatha i-Ilumya, i-TB yakho inokuqalisa ukusebenza. Ukuba uvavanyo lubonisa ukuba une-TB efihlakeleyo, kuyakufuneka ufumane unyango lwe-TB ngaphambi okanye ngexesha lonyango lwakho no-Ilumya.

Ixesha

Inaliti yokuqala neyesibini ye-Ilumya inikwa iiveki ezine ngokwahlukana. Emva kwala madosi mabini okuqala, uya kubuyela e-ofisini kagqirha rhoqo emva kweeveki ezili-12 kwenye idosi. Ukuba uphoswa idinga okanye idosi, yenza enye idinga ngokukhawuleza.

Usebenza kanjani u-Ilumya

I-Plaque psoriasis sisifo sokuzimela, yimeko ebangela ukuba amajoni omzimba asebenze kakhulu. I-Plaque psoriasis ibangela iiseli ezimhlophe zegazi, ezinceda umzimba ukulwa izifo, ukuba zihlasele ngempazamo iiseli zomntu. Oku kubangela ukuba iiseli zolusu zahlule ngokukhawuleza kwaye zikhule.

Iiseli zolusu ziveliswa ngokukhawuleza kangangokuba iiseli ezindala azinalo ixesha lokuwa kwaye zenza indawo yeeseli ezintsha. Ukuveliswa ngokugqithisileyo kunye nokwakhiwa kweeseli zolusu kubangela ukudumba, isikhumba, amabala esikhumba abuhlungu abizwa ngokuba ngamacwecwe.

I-Ilumya yi-monoclonal antibody, eluhlobo lwesiyobisi esivela kwiiseli zomzimba ezikwilabhoratri. Ama-antibodies e-Monoclonal ajolise kwiindawo ezithile zomzimba.

I-Ilumya ibhloka isenzo seprotein yamajoni omzimba ebizwa ngokuba yi-interleukin-23 (IL-23). Nge-plaque psoriasis, i-IL-23 isebenze ngamachiza abangela ukuba amajoni omzimba ahlasele iiseli zolusu. Ngokuthintela i-IL-23, i-Ilumya inceda ukunciphisa ukwakhiwa kweeseli zolusu kunye namacwecwe.

Ngenxa yokuba i-Ilumya ibhloka umsebenzi we-IL-23, kubhekiswa kuyo njenge-interleukin inhibitor.

Kuthatha ixesha elingakanani ukusebenza?

U-Ilumya uya kuqala ukusebenza ngokukhawuleza nje ukuba uqale ukuyithatha. Nangona kunjalo, kuthatha ixesha ukwakha kwinkqubo yakho kwaye kusebenze ngokupheleleyo, kungade kube ziiveki ezimbalwa ngaphambi kokuba ubone naziphi na iziphumo.

Kwizifundo zeklinikhi, emva kweveki enye yonyango, bangaphantsi kweepesenti ezingama-20 zabantu abathatha i-Ilumya babone ukuphuculwa kwamacwecwe. Nangona kunjalo, emva kweeveki ezili-12, ngaphezulu kwesiqingatha sabantu abafumene i-Ilumya babone ukuphucuka okukhulu kwiimpawu zabo ze-psoriasis. Inani labantu abaneempawu eziphuculweyo liyaqhubeka ukwanda kwiiveki ezingama-28 zonyango.

Ilumya kunye nokukhulelwa

Ayaziwa ukuba i-Ilumya ikhuselekile ukusebenzisa ngexesha lokukhulelwa. Izifundo zezilwanyana zibonise umngcipheko kwimveku engekazalwa xa u-Ilumya enikwa umntu obhinqileyo okhulelweyo. Nangona kunjalo, izifundo zezilwanyana azihlali ziqikelela ukuba kuya kwenzeka ntoni ngabantu.

Ukuba ukhulelwe okanye uceba ukukhulelwa, thetha nogqirha wakho malunga nezibonelelo kunye nobungozi bonyango lwe-Ilumya ngexesha lokukhulelwa.

Ilumya kunye nokuncancisa

Ayaziwa ukuba i-Ilumya idlula kubisi lwebele lomntu. Kwizifundo zezilwanyana, u-Ilumya wadlulela kubisi lwebele, eveza ukuncancisa okuncinci kwichiza. Nangona kunjalo, izifundo zezilwanyana azihlali ziqikelela ukuba kuya kwenzeka ntoni ebantwini.

Ukuba ucinga unyango lwe-Ilumya ngelixa uncancisa, thetha nogqirha wakho malunga nezibonelelo kunye neengozi.

Imibuzo eqhelekileyo malunga ne-Ilumya

Nazi iimpendulo kwimibuzo ebuzwa rhoqo malunga ne-Ilumya.

Ngaba i-Ilumya iyayinyanga i-plaque psoriasis?

Hayi, u-Ilumya akayinyangi i-plaque psoriasis. Okwangoku alikho iyeza lokunyanga esi sifo. Nangona kunjalo, unyango nge-Ilumya lunokunceda ukuphucula iimpawu zakho ze-psoriasis.

Ndisoloko ndisebenzisa iikhrimu kwi-plaque psoriasis yam. Kutheni le nto kufuneka ndiqale ukufumana inaliti?

Ugqirha wakho usenokuba uthathe isigqibo sokuba unyango lwenkqubo lunokwenza ngaphezulu ukunciphisa iimpawu zakho kunezithambiso zakho. Amachiza enkqubo anikwa ngenaliti okanye athathwe ngomlomo kwaye asebenze kuwo wonke umzimba.

Unyango lwenkqubo efana ne-Ilumya ngokubanzi lusebenza ngakumbi ekuphuculeni iimpawu ze-psoriasis kunonyango lwesihloko (iziyobisi ezisetyenziswa kulusu). Kungenxa yokuba basebenza ngaphakathi nangaphandle. Bajolise kumajoni omzimba ngokwawo, nto leyo ebangela ukuba ukhangelo lwepsoriasis lwakho. Oku kunokunceda kucace kwaye kuthintele iiplagi ze-psoriasis.

Ngonyango, ngakwelinye icala, ziphatha iiplagi emva kokuba zenziwe.

Unyango lwenkqubo ngamanye amaxesha lusetyenziswa ngokudibanisa kunye, okanye endaweni yoko, unyango lwezihloko. Zingasetyenziswa ukuba:

• amayeza ezincokolayo aziziphuculi ngokwaneleyo iimpawu zakho zeclac psoriasis, okanye
• Amacwecwe agubungela isahlulo esikhulu solusu lwakho (iipesenti ezi-3 nangaphezulu), nto leyo eyenza ukuba unyango lwezihloko lungasebenzi. Oku kuthathwa njengeliphakathi ukuya kwi-psoriasis ebukhali.

Ndiza kuthatha ixesha elingakanani ukuthatha i-Ilumya?

Ungamthatha u-Ilumya ixesha elide ukuba wena nogqirha wakho nithatha isigqibo sokuba u-Ilumya ukhuselekile kwaye uyasebenza kuwe.

Yintoni iziyobisi zebhayoloji?

Iyeza elenziwe ngebhayoloji lonyango elenziwe kwiiproteni zabantu okanye zezilwanyana. Amachiza e-biologic asetyenziselwa ukunyanga izifo ezenzekelayo, ezinje nge-plaque psoriasis, esebenza ngokudibana kunye namajoni omzimba. Benza oku ngeendlela ekujolise kuzo ukunciphisa ukudumba kunye nezinye iimpawu zesistim somzimba sokuzikhusela komzimba.

Ngenxa yokuba zinxibelelana neeseli ezithile zomzimba kunye neeproteni, i-biologics icingelwa ukuba ineziphumo ebezingalindelekanga ezimbalwa xa kuthelekiswa neziyobisi ezichaphazela uluhlu olubanzi lweenkqubo zomzimba, njengoko zininzi iziyobisi ezenzayo.

Xa zisetyenziselwa ukunyanga i-psoriasis, iziyobisi ze-biologic zihlala zisetyenziselwa abantu abane-plaque psoriasis engaphenduliyo kolunye unyango (njengonyango lwesihloko).

Ngaba i-Ilumya isetyenziselwa ukunyanga i-psoriatic arthritis?

U-Ilumya akagunyaziswanga yi-FDA ukunyanga i-psoriatic arthritis, kodwa inokusetyenziselwa ngaphandle kwelebheli ukulungiselela loo njongo.

Kwisifundo esinye seklinikhi esincinci, u-Ilumya akazange aziphucule ngokubonakalayo iimpawu ze-psoriatic arthritis okanye iintlungu, kodwa kwenziwa izifundo ezongezelelweyo ukuvavanya ukuba iluncedo kusini na kule meko. Olunye uphononongo lweklinikhi lwexesha elide luyaqhubeka ngoku.

Kutheni ndifuna uvavanyo lwe-TB phambi kokuba ndiqale unyango kunye no-Ilumya?

Ugqirha wakho uya kukuvavanya ukuba unesifo sephepha esisebenzayo okanye esifihlakeleyo ngaphambi kokuba uqale unyango nge-Ilumya. Abantu abane-TB esafukamileyo abanokwazi ukuba bosulelekile kuba akusoloko kubakho zimpawu. Uvavanyo lwegazi kuphela kwendlela yokwazi ukuba ngaba umntu one-TB efihlakeleyo akasosulelekanga na.

Ukuvavanyelwa i-TB ngaphambi konyango nge-Ilumya kubalulekile kuba u-Ilumya wenza buthathaka amajoni omzimba. Xa amajoni omzimba ebuthathaka, awunako ukulwa usulelo, kwaye i-TB efihlakeleyo inokuqalisa ukusebenza. Iimpawu ze-TB esebenzayo zibandakanya umkhuhlane, ukudinwa, ukwehla kobunzima, ukukhohlela igazi kunye nentlungu esifubeni.

Ukuba uvavanyiwe une-TB, kuyakufuneka ufumane unyango lwe-TB ngaphambi kokuba uqale i-Ilumya.

Ndingenza ntoni ukuthintela usulelo ngelixa ndithatha i-Ilumya?

Unyango lwe-Ilumya lwenza buthathaka amajoni akho omzimba kwaye lonyuse umngcipheko wosulelo. Imizekelo yosulelo olo ibandakanya isifo sephepha, ukuqaqanjelwa sisisu, usulelo lokungunda kunye nosulelo lokuphefumla.

Nangona kunjalo, zininzi izinto onokuzenza ukunceda ukuthintela usulelo:

• Hlala usesikhathini malunga nokugonywa, kubandakanywa nomkhuhlane (umkhuhlane).
• Kuphephe ukutshaya.
• Hlamba izandla zakho ngesepha rhoqo.
• Landela ukutya okusempilweni.
• Lala ngokwaneleyo.
• Kuphephe ukuba phakathi kwabantu abagulayo, ukuba kunokwenzeka.

Izilumkiso zika-Ilumya

Ngaphambi kokuba uthathe u-Ilumya, thetha nogqirha wakho malunga nembali yakho yezempilo. I-Ilumya isenokungakulungeli ukuba uneemeko ezithile zonyango. Oku kubandakanya:

• Imbali yempendulo ye-hypersensitivity ku-Ilumya okanye nasiphi na isithako sayo. Ukuba ubukhe wasabela kabuhlungu ku-Ilumya ngaphambili, akufuneki ufumane unyango ngeli chiza. Iziphumo ezinamandla zibandakanya ukudumba kobuso okanye ulwimi kunye nengxaki yokuphefumla.
• Usulelo olusebenzayo okanye imbali yosulelo oluphindaphindiweyo. I-Ilumya akufuneki iqalwe ngabantu abanosulelo lwangoku okanye imbali yosulelo oluphindaphindiweyo. Ukuba uphuhlisa usulelo ngelixa uthatha u-Ilumya, xelela ugqirha wakho ngoko nangoko. Baza kukubeka esweni ngokusondeleyo kwaye banokugqiba ekubeni bayeke unyango lwakho lwe-Ilumya de lunyangeke usulelo.
• Isifo sephepha. Ukuba une-TB equbisanayo okanye i-TB esebenzayo, unokufuna unyango lwe-TB ngaphambi kokuba uqale i-Ilumya. Akufanele uqale i-Ilumya ukuba une-TB esebenzayo. (Ukuba une-TB efihlakeleyo, ugqirha wakho usenokuqalisa ukuthatha i-Ilumya ngexesha lonyango lwakho lwe-TB.)

Ulwazi lobungcali ku-Ilumya

Olu lwazi lulandelayo lubonelelwe ngoochwephesha kunye nabanye abaqeqeshi bezempilo.

Indlela yokusebenza

I-Ilumya iqulethe i-humanococonal monoclonal antibody tildrakizumab. Ibopha kwi-p19 subunit ye-interleukin-23 (IL-23) cytokine kwaye iyithintele ekubambeni kwi-IL-23 receptor. Ukuthintela umsebenzi we-IL-23 kuthintela ukwenziwa kwenkqubo ye-T-helper cell 17 (Th17) yendlela.

I-Pharmacokinetics kunye ne-metabolism

Ukungafumaneki ngokupheleleyo kwi-bioavailability kuye kuthi ga kwiipesenti ezingama-80 kulandela inaliti engaphantsi. Ukugxininiswa kwencopho kufikelelwe kwiintsuku ezintandathu. Ukuxinana okuzinzileyo kufikelelwe ngeveki ye-16.

I-Ilumya yathotywa yazi peptides ezincinci kunye neeamino acid ngokusebenzisa ikatabolism. Ukupheliswa kwesiqingatha sobomi malunga neentsuku ezingama-23.

Ukungqinelana

I-Ilumya iyaphikiswa kwizigulana ezinembali yokusabela gwenxa kweziyobisi okanye nayiphi na into eyincedayo.

Isitofu

Kulumkele ukugonyelwa bukhoma kwizigulana ezifumana i-Ilumya.

Ukunyanga kwangaphambili

Zonke izigulana kufuneka zivavanyelwe isifo sephepha esifunyenwe kade okanye esisebenzayo ngaphambi konyango lwe-Ilumya. Sukuyisebenzisa i-Ilumya kwizigulana ezine-TB esebenzayo. Izigulana ezine-TB esafukamileyo kufuneka ziqale unyango lwe-TB ngaphambi kokuba ziqale unyango kunye no-Ilumya.

Ukugcina

Ilumya kufuneka igcinwe kwifriji kwi-36⁰F ukuya kwi-46⁰F (2⁰C ukuya kwi-8⁰C). Gcina kwisikhongozeli sokuqala ukukhusela ekukhanyeni. I-Ilumya inokugcinwa kubushushu begumbi-ukuya kuthi ga kwi-77⁰F (25⁰C) -ukuya kwiintsuku ezingama-30. Nje ukuba ugcinwe kubushushu begumbi, musa ukubuyela kwifriji. Musa ukubanda okanye ugungqe. Vumela u-Ilumya ahlale kubushushu begumbi kangangemizuzu engama-30 ngaphambi kolawulo.

Ukuziphendulela: I-MedicalNewsToday yenze yonke imizamo yokuqinisekisa ukuba yonke ingcaciso ichanekile, ibanzi kwaye ihlaziyiwe. Nangona kunjalo, eli nqaku akufuneki lisetyenziswe endaweni yolwazi kunye nobuchule bengcali yezempilo enelayisensi. Kuya kufuneka usoloko uqhagamshelana nogqirha wakho okanye nolunye uqeqesho kwezonyango ngaphambi kokuba uthathe nawaphi na amayeza. Ulwazi lweziyobisi oluqulethwe apha luyakwazi ukutshintsha kwaye alujoliswanga ekusetyenzisweni konke okunokwenzeka, imikhombandlela, izilumkiso, izilumkiso, ukuhlangana kweziyobisi, ukungahambelani komzimba, okanye iziphumo ezibi. Ukungabikho kwezilumkiso okanye olunye ulwazi ngesiyobisi esinikiweyo akubonisi ukuba indibaniselwano yeziyobisi ikhuselekile, iyasebenza, okanye ifanelekile kuzo zonke izigulana okanye konke ukusetyenziswa okuthile.